Michiel G Betjes

List of Publications by Year in Descending Order

116 papers	3,688 citations	34 h-index	57 g-index
119 ext. papers	4,477 ext. citations	5.1 avg, IF	5.82 L-index

#	Paper	IF	Citations
116	Current Tolerance-Associated Peripheral Blood Gene Expression Profiles After Liver Transplantation Are Influenced by Immunosuppressive Drugs and Prior Cytomegalovirus Infection.. *Frontiers in Immunology*, **2021**, 12, 738837	8.4	0
115	T-Cell Epitopes Shared Between Immunizing HLA and Donor HLA Associate With Graft Failure After Kidney Transplantation. *Frontiers in Immunology*, **2021**, 12, 784040	8.4	1
114	Creating Options for Difficult-to-match Kidney Transplant Candidates. *Transplantation*, **2021**, 105, 240-248	4.8	1
113	Uremia-Associated Immunological Aging and Severity of COVID-19 Infection. *Frontiers in Medicine*, **2021**, 8, 675573	4.9	6
112	Expression of Senescence Marker TIGIT Identifies Polyfunctional Donor-Reactive CD4+ T Cells Preferentially Lost After Kidney Transplantation. *Frontiers in Immunology*, **2021**, 12, 656846	8.4	1
111	The FCGR3A 158V/V-genotype is associated with decreased survival of renal allografts with chronic active antibody-mediated rejection. *Scientific Reports*, **2021**, 11, 7903	4.9	3
110	Activated CD4 T Cells and Highly Differentiated Alloreactive CD4 T Cells Distinguish Operationally Tolerant Liver Transplantation Recipients. *Liver Transplantation*, **2021**,	4.5	2
109	ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts. *Human Immunology*, **2021**, 82, 89-96	2.3	3
108	Is simplification of immunosuppressive medication a way to promote medication adherence of kidney transplant recipients? Findings from a randomized controlled trial. *Transplant International*, **2021**, 34, 1703-1711	3	1
107	Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys. *Transplantation Proceedings*, **2021**, 53, 2206-2211	1.1	1
106	COVID-19 in solid organ transplant recipients: a single-center experience. *Transplant International*, **2020**, 33, 1099-1105	3	56
105	High numbers of differentiated CD28null CD8+ T cells are associated with a lowered risk for late rejection and graft loss after kidney transplantation. *PLoS ONE*, **2020**, 15, e0228096	3.7	4
104	A very low thymus function identifies patients with substantial increased risk for long-term mortality after kidney transplantation. *Immunity and Ageing*, **2020**, 17, 4	9.7	8
103	Pretransplant Donor-Specific Anti-HLA Antibodies and the Risk for Rejection-Related Graft Failure of Kidney Allografts. *Journal of Transplantation*, **2020**, 2020, 5694670	2.3	3
102	Validation of a Combined Transcriptome and T Cell Receptor Alpha/Beta (TRA/TRB) Repertoire Assay at the Single Cell Level for Paucicellular Samples. *Frontiers in Immunology*, **2020**, 11, 1999	8.4	2
101	Uremia-Associated Ageing of the Thymus and Adaptive Immune Responses. *Toxins*, **2020**, 12,	4.9	14
100	High numbers of differentiated CD28null CD8+ T cells are associated with a lowered risk for late rejection and graft loss after kidney transplantation **2020**, 15, e0228096		

99	High numbers of differentiated CD28null CD8+ T cells are associated with a lowered risk for late rejection and graft loss after kidney transplantation **2020**, 15, e0228096		
98	High numbers of differentiated CD28null CD8+ T cells are associated with a lowered risk for late rejection and graft loss after kidney transplantation **2020**, 15, e0228096		
97	High numbers of differentiated CD28null CD8+ T cells are associated with a lowered risk for late rejection and graft loss after kidney transplantation **2020**, 15, e0228096		
96	High numbers of differentiated CD28null CD8+ T cells are associated with a lowered risk for late rejection and graft loss after kidney transplantation **2020**, 15, e0228096		
95	High numbers of differentiated CD28null CD8+ T cells are associated with a lowered risk for late rejection and graft loss after kidney transplantation **2020**, 15, e0228096		
94	The aftermath of acute kidney injury: a narrative review of long-term mortality and renal function. *Critical Care*, **2019**, 23, 24	10.8	56
93	Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection. *BMC Nephrology*, **2019**, 20, 218	2.7	13
92	Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients. *American Journal of Transplantation*, **2019**, 19, 2926-2933	8.7	14
91	Antibodies against ARHGDIB are associated with long-term kidney graft loss. *American Journal of Transplantation*, **2019**, 19, 3335-3344	8.7	27
90	Predictors of short-term successful discontinuation of continuous renal replacement therapy: results from a prospective multicentre study. *BMC Nephrology*, **2019**, 20, 129	2.7	13
89	Increased CD16 expression on NK cells is indicative of antibody-dependent cell-mediated cytotoxicity in chronic-active antibody-mediated rejection. *Transplant Immunology*, **2019**, 54, 52-58	1.7	13
88	Immune Cell Infiltrate in Chronic-Active Antibody-Mediated Rejection. *Frontiers in Immunology*, **2019**, 10, 3106	8.4	17
87	Banff lesions and renal allograft survival in chronic-active antibody mediated rejection. *Transplant Immunology*, **2019**, 56, 101213	1.7	6
86	Predictors of 90-Day Restart of Renal Replacement Therapy after Discontinuation of Continuous Renal Replacement Therapy, a Prospective Multicenter Study. *Blood Purification*, **2019**, 48, 243-252	3.1	5
85	Toward a Sensible Single-antigen Bead Cutoff Based on Kidney Graft Survival. *Transplantation*, **2019**, 103, 789-797	1.8	15
84	Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients. *Nephrology Dialysis Transplantation*, **2019**, 34, 1417-1422	4.3	2
83	Chronic-active antibody-mediated rejection with or without donor-specific antibodies has similar histomorphology and clinical outcome - a retrospective study. *Transplant International*, **2018**, 31, 900-908	3	20
82	Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells. *Stem Cells*, **2018**, 36, 602-615	5.8	231

81	PIRCHE-II Is Related to Graft Failure after Kidney Transplantation. *Frontiers in Immunology*, **2018**, 9, 321	8.4	37
80	Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. *PLoS ONE*, **2018**, 13, e0196552	3.7	20
79	Differentially methylated regions in T cells identify kidney transplant patients at risk for de novo skin cancer. *Clinical Epigenetics*, **2018**, 10, 81	7.7	11
78	"What if this is my chance to save my life?" A semistructured interview study on the motives and experiences of end-stage renal disease patients who engaged in public solicitation of a living kidney donor. *Transplant International*, **2018**, 31, 318-331	3	3
77	Development and Validation of a Multiplex Non-HLA Antibody Assay for the Screening of Kidney Transplant Recipients. *Frontiers in Immunology*, **2018**, 9, 3002	8.4	15
76	A comprehensive characterization of aggravated aging-related changes in T lymphocytes and monocytes in end-stage renal disease: the iESRD study. *Immunity and Ageing*, **2018**, 15, 27	9.7	29
75	Renal function at 1 year after cardiac transplantation rather than acute kidney injury is highly associated with long-term patient survival and loss of renal function - a retrospective cohort study. *Transplant International*, **2017**, 30, 788-798	3	12
74	Significant Decreasing Incidence of Encapsulating Peritoneal Sclerosis in the Dutch Population of Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2017**, 37, 230-234	2.8	23
73	pERK-dependent defective TCR-mediated activation of CD4 T cells in end-stage renal disease patients. *Immunity and Ageing*, **2017**, 14, 14	9.7	9
72	Interferon-Gamma DNA Methylation Is Affected by Mycophenolic Acid but Not by Tacrolimus after T-Cell Activation. *Frontiers in Immunology*, **2017**, 8, 822	8.4	9
71	Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function. *Frontiers in Immunology*, **2017**, 8, 1042	8.4	67
70	Protective Cytomegalovirus (CMV)-Specific T-Cell Immunity Is Frequent in Kidney Transplant Patients without Serum Anti-CMV Antibodies. *Frontiers in Immunology*, **2017**, 8, 1137	8.4	16
69	T-Cell Composition of the Lymph Node Is Associated with the Risk for Early Rejection after Renal Transplantation. *Frontiers in Immunology*, **2017**, 8, 1416	8.4	4
68	End-Stage Renal Disease Causes Skewing in the TCR V Repertoire Primarily within CD8 T Cell Subsets. *Frontiers in Immunology*, **2017**, 8, 1826	8.4	11
67	Clinical consequences of circulating CD28-negative T cells for solid organ transplantation. *Transplant International*, **2016**, 29, 274-84	3	16
66	Loss of CD28 on Peripheral T Cells Decreases the Risk for Early Acute Rejection after Kidney Transplantation. *PLoS ONE*, **2016**, 11, e0150826	3.7	26
65	Vascular Multiplicity Should Not Be a Contra-Indication for Live Kidney Donation and Transplantation. *PLoS ONE*, **2016**, 11, e0153460	3.7	14
64	Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation. *Clinical Epigenetics*, **2016**, 8, 116	7.7	12

63	Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis. *BMC Medicine*, **2015**, 13, 111	11.4	101
62	Allogeneic Mature Human Dendritic Cells Generate Superior Alloreactive Regulatory T Cells in the Presence of IL-15. *Journal of Immunology*, **2015**, 194, 5282-93	5.3	12
61	A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood. *BMC Research Notes*, **2015**, 8, 266	2.3	2
60	ABO-incompatible kidney transplant recipients have a higher bleeding risk after antigen-specific immunoadsorption. *Transplant International*, **2015**, 28, 25-33	3	29
59	End stage renal disease patients have a skewed T cell receptor V repertoire. *Immunity and Ageing*, **2015**, 12, 28	9.7	14
58	Ureteral length in live donor kidney transplantation; Does size matter?. *Transplant International*, **2015**, 28, 1326-31	3	4
57	Post-Transplantation Immunoadsorption Can Be Withheld in ABO-Incompatible Kidney Transplant Recipients. *Therapeutic Apheresis and Dialysis*, **2015**, 19, 513-7	1.9	3
56	Long-term sequelae of severe acute kidney injury in the critically ill patient without comorbidity: a retrospective cohort study. *PLoS ONE*, **2015**, 10, e0121482	3.7	9
55	Alternative Living Kidney Donation Programs Boost Genetically Unrelated Donation. *Journal of Transplantation*, **2015**, 2015, 748102	2.3	4
54	Encapsulating peritoneal sclerosis is associated with T-cell activation. *Nephrology Dialysis Transplantation*, **2015**, 30, 1568-76	4.3	10
53	Chronic kidney disease and premature ageing of the adaptive immune response. *Current Urology Reports*, **2015**, 16, 471	2.9	34
52	CD4-Positive T Cells and M2 Macrophages Dominate the Peritoneal Infiltrate of Patients with Encapsulating Peritoneal Sclerosis. *PLoS ONE*, **2015**, 10, e0120174	3.7	12
51	Uremia-associated immunological aging is stably imprinted in the T-cell system and not reversed by kidney transplantation. *Transplant International*, **2014**, 27, 1272-84	3	42
50	Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. *Transplantation*, **2014**, 97, 47-55	1.8	16
49	Histological and clinical findings in patients with post-transplantation and classical encapsulating peritoneal sclerosis: a European multicenter study. *PLoS ONE*, **2014**, 9, e106511	3.7	15
48	Patients with encapsulating peritoneal sclerosis have increased peritoneal expression of connective tissue growth factor (CCN2), transforming growth factor-1, and vascular endothelial growth factor. *PLoS ONE*, **2014**, 9, e112050	3.7	26
47	Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: a 2-year follow-up study. *Journal of Transplantation*, **2014**, 2014, 675301	2.3	42
46	The First Fifty ABO Blood Group Incompatible Kidney Transplantations: The Rotterdam Experience. *Journal of Transplantation*, **2014**, 2014, 913902	2.3	18

45	The impact of induction therapy on the homeostasis and function of regulatory T cells in kidney transplant patients. *Nephrology Dialysis Transplantation*, **2014**, 29, 1587-97	4.3	36
44	Update on controls for isolation and quantification methodology of extracellular vesicles derived from adipose tissue mesenchymal stem cells. *Frontiers in Immunology*, **2014**, 5, 525	8.4	58
43	Rotterdam: main port for organ transplantation research in the Netherlands. *Transplant Immunology*, **2014**, 31, 200-6	1.7	1
42	T-cell ageing in end-stage renal disease patients: Assessment and clinical relevance. *World Journal of Nephrology*, **2014**, 3, 268-76	3.6	25
41	Mesenchymal stem cells induce an inflammatory response after intravenous infusion. *Stem Cells and Development*, **2013**, 22, 2825-35	4.4	89
40	Immune cell dysfunction and inflammation in end-stage renal disease. *Nature Reviews Nephrology*, **2013**, 9, 255-65	14.9	286
39	Lower mortality and inflammation from post-transplantation encapsulating peritoneal sclerosis compared to the classical form. *American Journal of Nephrology*, **2013**, 37, 223-30	4.6	19
38	Novel biomarkers for the prediction of acute kidney injury in patients undergoing liver transplantation. *Biomarkers in Medicine*, **2013**, 7, 947-57	2.3	15
37	Loss of renal function causes premature aging of the immune system. *Blood Purification*, **2013**, 36, 173-8	3.1	43
36	Kinetics of homeostatic proliferation and thymopoiesis after rATG induction therapy in kidney transplant patients. *Transplantation*, **2013**, 96, 904-13	1.8	29
35	Circulating CD4(+)CD28null T Cells May Increase the Risk of an Atherosclerotic Vascular Event Shortly after Kidney Transplantation. *Journal of Transplantation*, **2013**, 2013, 841430	2.3	13
34	Human Bone Marrow- and Adipose Tissue-derived Mesenchymal Stromal Cells are Immunosuppressive and in a Humanized Allograft Rejection Model. *Journal of Stem Cell Research & Therapy*, **2013**, Suppl 6, 20780	1	29
33	Human Allogeneic Bone Marrow and Adipose Tissue Derived Mesenchymal Stromal Cells Induce CD8+ Cytotoxic T Cell Reactivity. *Journal of Stem Cell Research & Therapy*, **2013**, 3, 004	1	13
32	Uremia causes premature ageing of the T cell compartment in end-stage renal disease patients. *Immunity and Ageing*, **2012**, 9, 19	9.7	68
31	Identification of circulating human antigen-reactive CD4+ FOXP3+ natural regulatory T cells. *Journal of Immunology*, **2012**, 188, 1083-90	5.3	30
30	Terminally differentiated CD8+ Temra cells are associated with the risk for acute kidney allograft rejection. *Transplantation*, **2012**, 94, 63-9	1.8	48
29	A killer on the road: circulating CD4(+)CD28null T cells as cardiovascular risk factor in ESRD patients. *Journal of Nephrology*, **2012**, 25, 183-91	4.8	30
28	Differential effects of age, cytomegalovirus-seropositivity and end-stage renal disease (ESRD) on circulating T lymphocyte subsets. *Immunity and Ageing*, **2011**, 8, 2	9.7	43

27	Premature aging of circulating T cells in patients with end-stage renal disease. *Kidney International*, **2011**, 80, 208-17	9.9	125
26	Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. *Peritoneal Dialysis International*, **2011**, 31, 269-78	2.8	73
25	Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. *Nephrology Dialysis Transplantation*, **2011**, 26, 691-7	4.3	68
24	Encapsulating peritoneal sclerosis: the state of affairs. *Nature Reviews Nephrology*, **2011**, 7, 528-38	14.9	72
23	Prevention of catheter-related bloodstream infection in patients on hemodialysis. *Nature Reviews Nephrology*, **2011**, 7, 257-65	14.9	49
22	Circulating pro-inflammatory CD4posCD28null T cells are independently associated with cardiovascular disease in ESRD patients. *Nephrology Dialysis Transplantation*, **2010**, 25, 3640-6	4.3	46
21	CMV seropositivity determines epoetin dose and hemoglobin levels in patients with CKD. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 2661-6	12.7	16
20	Reversible renal failure due to bilateral renal sarcoma in a patient with acute myeloid leukemia. *Renal Failure*, **2009**, 31, 606-9	2.9	6
19	Resolution of IgM nephropathy after rituximab treatment. *American Journal of Kidney Diseases*, **2009**, 53, 1059-62	7.4	13
18	The human alloreactive CD4+ T-cell repertoire is biased to a Th17 response and the frequency is inversely related to the number of HLA class II mismatches. *Blood*, **2009**, 114, 3947-55	2.2	24
17	Hepatitis B vaccine-specific CD4(+) T cells can be detected and characterised at the single cell level: limited usefulness of dendritic cells as signal enhancers. *Journal of Immunological Methods*, **2008**, 330, 1-11	2.5	26
16	IL-2 producing memory CD4+ T lymphocytes are closely associated with the generation of IgG-secreting plasma cells. *Journal of Immunology*, **2008**, 181, 3665-73	5.3	44
15	Expansion of cytolytic CD4+CD28- T cells in end-stage renal disease. *Kidney International*, **2008**, 74, 760-7	9.9	85
14	Hydroxyethylstarch solutions versus saline for the treatment of intradialytic hypotension. *Journal of Renal Care*, **2007**, 33, 130-3	1.6	
13	Posttransplant Encapsulating Peritoneal Sclerosis: A Worrying New Trend?. *Peritoneal Dialysis International*, **2007**, 27, 619-624	2.8	86
12	Seropositivity for cytomegalovirus in patients with end-stage renal disease is strongly associated with atherosclerotic disease. *Nephrology Dialysis Transplantation*, **2007**, 22, 3298-303	4.3	53
11	Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. *Journal of Nephrology*, **2007**, 20, 602-8	4.8	72
10	Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. *Clinical Immunology*, **2006**, 118, 83-91	9	107

9	The pathology of jaundice-related renal insufficiency: cholemic nephrosis revisited. *Journal of Nephrology*, **2006**, 19, 229-33	4.8	60
8	The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. *Nephrology Dialysis Transplantation*, **2005**, 20, 1868-73	4.3	44
7	Vitamin E-coated dialyzer membranes downregulate expression of monocyte adhesion and co-stimulatory molecules. *Blood Purification*, **2004**, 22, 510-7	3.1	11
6	Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. *Kidney International*, **2004**, 66, 614-21	9.9	58
5	Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. *Nephrology Dialysis Transplantation*, **2004**, 19, 1546-51	4.3	172
4	Intraperitoneal Interleukin-8 and Neutrophil Influx in the Initial Phase of a Capd Peritonitis. *Peritoneal Dialysis International*, **1996**, 16, 385-392	2.8	27
3	Analysis of Inflammatory Mediators and Peritoneal Permeability to Macromolecules Shortly before the Onset of Overt Peritonitis in Patients Treated with CAPD. *Peritoneal Dialysis International*, **1995**, 15, 134-141	2.8	33
2	Interleukin-8 production by human peritoneal mesothelial cells in response to tumor necrosis factor-alpha, interleukin-1, and medium conditioned by macrophages cocultured with Staphylococcus epidermidis. *Journal of Infectious Diseases*, **1993**, 168, 1202-10	7	117
1	Immuno-effector characteristics of peritoneal cells during CAPD treatment: a longitudinal study. *Kidney International*, **1993**, 43, 641-8	9.9	56